COMPARATIVE EVALUATION OF ACAMPROSATE WITH OTHER DRUGS IN CENTRAL TINNITUS

Sharanjit Kaur, Harinder jot Singh, Naresh Jyoti

1. Assistant Professor. Department of Pharmacology, CMCH, Pathankot.
2. Assistant Professor. Department of Physiology, CMCH, Pathankot.
3. Assistant Professor. Department of Pharmacology, CMCH, Pathankot.

CORRESPONDING AUTHOR:
Dr. Sharanjit Kaur,
H. No. 39-A Rattan Nagar,
Tripuri Town Patiala,
E-mail: drsharan25@gmail.com
Ph: 0091 9781327788

ABSTRACT: AIM: To compare the efficacy of acamprosate with other drugs to decrease the severity of sensorineural tinnitus. MATERIAL AND METHOD: The study was randomised double-blind, placebo controlled, crossover. Forty adult subjects (>18 years of age), of either sex with tinnitus of sensorineural origin, were administered either acamprosate 333 mg tds or matched placebo for a period of six weeks followed by a washout period of one week. Drug therapy was switched for another six weeks in consonance with the crossover design. The effect of acamprosate and placebo on subjective relief and objective improvement was evaluated by using modified tinnitus severity quality of life scores and audiometry with tinnitus matching in frequency and loudness. RESULTS: At the end of study the drug had shown a statistically significant improvement in reducing the tinnitus score in 92.5% of the patients and placebo with an improvement in 12.5% of the patients in contrast to other drugs belonging to this group. CONCLUSION: Acamprosate is an effective drug in treating the severity of sensorineural tinnitus

KEYWORDS: Sensorineural tinnitus, tinnitus matching, acamprosate

INTRODUCTION: Tinnitus is characterized by the perception of sound or noise in the absence of any internal or external acoustical stimulation.1 Increase in the release of Glutamate; the major neurotransmitter both in the cochlea and in the central auditory pathways, has been suggested to be involved in the generation and maintenance of sensorineural tinnitus by causing “excitotoxicity”.2 In recent years therapy for tinnitus has focused on drugs that act directly on CNS neurotransmitters, like glutamate, GABA, serotonin, acetylcholine and dopamine. Glutamate receptor antagonists which block glutamate binding sites and prevent/attenuate the influx of calcium can be useful for the condition.3 Acamprosate which acts by a dual mechanism of action, both as a glutamate antagonist and as a GABA agonist reported a relief of tinnitus in over 80% of patients in a double blind study.4

AIMS AND OBJECTIVES: To compare the efficacy of acamprosate with other drugs to decrease the severity of sensorineural tinnitus.

MATERIAL AND METHOD: The protocol for study was submitted to the Institutional Ethics Committee (IEC) and approval was sought. After getting approval from concerned authorities, 40 subjects were included in the present study.
SUBJECTS: Forty adult subjects (>18 years of age), of either sex and suffering from unilateral, bilateral or generalized tinnitus of sensorineural origin, presenting at the Outpatient Department of Ram Lal Eye and Ear, Nose and Throat Hospital and volunteering to participate, were included in this study.

Informed consent was taken from the patient after giving all the aspects of the study.

Type of study: Prospective, randomized, placebo controlled, double-blind, cross over design.

A complete medical history and general physical examination was recorded on a prescribed Performa from all the patients.

Following tuning fork tests were performed to make a preliminary assessment of type and amount of hearing loss:

- Rinne’s Test using tuning forks of 256, 512 and 1024 Hz.
- Weber’s Test using tuning forks of 512 Hz.
- Absolute Bone conduction test using tuning fork of 512 Hz.5

All the patients were then subjected to Pure Tone Audiometry and tinnitus matching in terms of frequency and loudness using AAA222 Inter-acoustic Audiometer.6

A validated questionnaire was used and filled by assisting the patient to quantify the impact of subjective sensation of tinnitus on patient’s ‘Quality of Life’ (QOL).7 The scoring system was done to quantify the severity of tinnitus and its impact on quality of life. These patients were also subjected to visual analogue scale for loudness in cm along a 10 cm scale.8

These patients were provided with acamprosate 333 mg tds or matched placebo for a period of fifteen days. They were instructed to maintain a diary to keep a record of medication intake and any significant events. They were instructed to come back to the ENT OPD every fifteen days to fill in the questionnaire, had their ENT examination and then received an additional fifteen day supply. This procedure repeated every fifteen days for the duration of the study.

Group I: tab. acamprosate 333mg 1 tab. P.O. thrice a day
Group II: matched placebo 1 tab. P.O. thrice a day

This schedule of treatment was continued for forty five days. Afterwards these patients were subjected to a washout period of seven days and later crossed over to acamprosate or placebo as follows for next forty five days.

Group I: matched placebo 1 tab. P.O. thrice a day
Group II: tab. acamprosate 333mg 1 tab. P.O. thrice a day

The effect of the drug was studied both as a subjective and objective improvement in Visual Analogue Score (VAS) or QOL questionnaire score. A decrease in tinnitus loudness was considered as objective improvement. The results were then compiled and analysed statistically by using student ‘t’ test for independent samples.

The criterion for determination of significance will be at 5%, with ‘p’ value of the statistical test smaller or equal to 0.05.

RESULTS: A total of forty five patients were taken. Two patients reported their conditions to be worse and they were shifted to another treatment. Three patients were lost during the study. Forty patients were able to complete the study. All of them had sensorineural hearing loss downward curve. In 65% of patients was bilateral hearing loss; in 35% of them had bilateral tinnitus.

The age of patients was 18 to 84 years with an average of 53 years.
The improvement score or reduction in tinnitus score was observed in 92.5% of patients included in this study as compared to previous study which showed an improvement score of 86.9% in 90 days. At the end of study only five patients (7.5%) showed no improvement as compared to 13.06% in previous study. Twenty-one patients (77.5%) reported improvement below 50%, six patients (15%) reported improvement higher than 50%. Five patients (12.5%) reported that their tinnitus had disappeared as compared to 13.04% in previous study as shown in table I.

To assess the progression of tinnitus throughout study time, we had performed the statistical analysis of each study group at first day, 45th day, 52nd day and 97th day in terms of VAS score and QOL questionnaires as shown in table III, IV, V. This improvement was also assessed objectively by psychoacoustic reduction in tinnitus matching. 20% did not show any improvement while 80% patients showed improvement in tinnitus loudness. The decrease in tinnitus loudness was varied from 5 db to zero as shown in table VI.

In placebo group, 12.5% reported improvement subjectively only as shown in table I and II.

Thus at the end of study, the drug had shown a statistically significant improvement in reducing the tinnitus score in 92.5% of the patients and placebo shown a little improvement in 12.5% of the patients. The subjective improvement was greater than objective improvement. The drug was well tolerated and did not show any serious drug reactions. No patient had any change in audiogram shape. Those patients who were fully treated or obtained the best results were those who had the symptoms for less time.

The subjective improvement was greater than objective improvement. The drug was well tolerated and did not show any serious drug reactions.

**DISCUSSION:** Tinnitus is defined as a phantom auditory perception — it is a perception of sound without corresponding acoustic or mechanical correlates in the cochlea. Tinnitus is a subjective phenomenon that is difficult to evaluate objectively, with it being measured, quantified, and described only based on the responses of patients.

It has been established that, that 35–40% of all adults over 17 years of age experience temporary or noises lasting longer than 5 minutes of various degrees of loudness at some time. A miniscule number of patients (0.5%) are in urgent need of treatment. These patients may also experience sleep disorders, poor concentration and depression leading to a vicious cycle from which there seems no escape. Another, 0.5–1% of adults report tinnitus of such severity so as to have a significant adverse effect on their quality of life.

Current treatments of tinnitus are not cures; they are a means to reduce tinnitus perception or awareness. Well controlled trials of management strategies are few and published success rates of most treatments remain controversial. Despite this there is sufficient evidence to advocate existing strategies to reduce tinnitus annoyance and improve quality of life.

All drugs investigated in this work are related to different groups with no specific action to decrease the severity of tinnitus. We are still left with undefined drugs. Considering such situation, any new perspective seems to be received as a novel alternative.

The introduction and application of new drug therapies have increased the success of tinnitus treatment. Many of the drug treatments that were aimed at level of the cochlea, e.g. using intratympanic injections of gentamicin, dexamethasone or lidocaine or the CNS using systemic delivery. Drugs like lidocaine have been shown to temporarily eliminate ear noise, but
have to be given intravenously and in doses so high that serious side effects are reported too often.\textsuperscript{13}

The use of antidepressants as a potential tinnitus treatment was initially very promising but has shown disappointing results on long term use. This has been primarily because of the complexity of the central nervous system, and the multifactorial causes of tinnitus.\textsuperscript{14}

Other drugs already studied for treatment of tinnitus are baclofen (improvement in about 9.7\%),\textsuperscript{15} caroverine (63.3\%),\textsuperscript{16} nimodipine (16.13\%),\textsuperscript{17} clonazepam (32\%)\textsuperscript{18} and trimetazidine (89\%).\textsuperscript{19}

Different studies have shown that sensorineural tinnitus is caused by an imbalance of two neurotransmitters Glutamate and GABA in the auditory pathway.\textsuperscript{20} The ability to modulate the action of neurotransmitters in afferent auditory pathway opens new possibilities in the therapy of this symptom.

Drugs affecting the GABA levels may show improvement in reducing the severity of tinnitus. Alprazolam in a double-blind, placebo-controlled study, reduced tinnitus loudness in 65\% of subjects compared to 5\% in the control group. Clonazepam, a long acting benzodiazepine significantly reduced tinnitus loudness (32\%) and annoyance relative to the control group.\textsuperscript{21} Vigabatrin and tiagabine two drugs that act on different aspects of GABAergic neurotransmission, have been studied in an animal model of noise-induced tinnitus.\textsuperscript{22} Clinical use of benzodiazepine is limited by their side effects such as high risk of drug dependency and personality changes.\textsuperscript{23}

Gabapentin a GABA-mimetic has shown encouraging results in the improvement of tinnitus in high doses. But there is little evidence to support a general use of gabapentin in subjective tinnitus.\textsuperscript{24}

Modulation of glutaminergic transmission by topical administration of the nonselective glutamate receptor antagonist caroverine to the inner ear has been proposed for tinnitus treatment. In a single-blind study subjects tinnitus loudness and tinnitus matching were measured before and after treatment and at 1 week post-treatment. Immediately post-treatment, 63\% of the caroverine group and 43\% of the placebo group showed a significant response. However, the systemic use of nonselective glutamate receptor blockers such as caroverine is limited by severe neurological and psychiatric side effects.\textsuperscript{16}

Memantine another NMDA receptor antagonist was used to evaluate its efficacy in tinnitus during a placebo controlled cross over study. But the results were not up to the mark to show its efficacy. It might be due to wrong dosage administered for inadequate period of time.\textsuperscript{25} Acamprosate in another clinical trial 87\% of the subjects in the acamprosate group showed improvement of 87\% of the subjects taking acamprosate including three subjects in whom tinnitus disappeared, compared to 44\% in the placebo group.\textsuperscript{4} (Table VII and GRAPH I)

Like memantine, neramexane acts as a noncompetitive, voltage-dependent NMDA antagonist. It also blocks \( \alpha_9 \) and \( \alpha_{10} \) nicotinic cholinergic receptors which are expressed on inner hair cells in the inner ear. In one large clinical trial this compound has shown a positive improvement in tinnitus handicap score as compared to placebo group.\textsuperscript{26}

\textbf{CONCLUSION:} The most accepted theory of glutamate neurotoxicity and benzodiazepine deficiency which is based on the receptor targeted therapy are responsible for the possible cause of the tinnitus of sensorineural in origin.
The rationale of treating tinnitus is based on modulation of these neurotransmitters in afferent auditory pathway by reducing the cytotoxicity and maintaining the cochlear homeostasis. There are only a few drugs that act specifically on the GABA-glutamate without showing any major undesirable side effects.

The drugs which affect the GABA levels are benzodiazepines and local anaesthetics like lidocaine. But these drugs show the site specificity and pharmacokinetic specificity, high risk of drug dependency and personality changes.

The drugs affecting the NMDA receptors are the new promising candidates for the treatment of central type tinnitus.

The acamprosate drug which acts through dual mechanism of increasing the GABA expression and decreasing the glutamate expression, work specifically on subgroup of tinnitus patients. Further in future ongiong clinical trials with appropriate size and sample may help to revolutionize the treatment of tinnitus.

BIBLIOGRAPHY:


**TABLE I: SUBJECTIVE IMPROVEMENT**

<table>
<thead>
<tr>
<th>Improvement score</th>
<th>During drug treatment</th>
<th>During placebo treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>No improvement</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>0- 25%</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>26-50%</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>51-75%</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>76-100%</td>
<td>5</td>
</tr>
</tbody>
</table>

**Table II: OBJECTIVE IMPROVEMENT**

<table>
<thead>
<tr>
<th>Improvement score</th>
<th>During drug treatment</th>
<th>During placebo treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>No improvement</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Decrease in tinnitus loudness</td>
<td>32</td>
<td>0</td>
</tr>
</tbody>
</table>
### TABLE III: VISUAL ANALOGUE SCALE SCORE FOR LOUDNESS OF TINNITUS

<table>
<thead>
<tr>
<th></th>
<th>VAS</th>
<th>1&lt;sup&gt;st&lt;/sup&gt; day</th>
<th>45&lt;sup&gt;th&lt;/sup&gt; day</th>
<th>52&lt;sup&gt;nd&lt;/sup&gt; day</th>
<th>97&lt;sup&gt;th&lt;/sup&gt; day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>7.1±1.17</td>
<td>4.2±1.95</td>
<td>4.15±1.95</td>
<td>4.05±1.98</td>
<td></td>
</tr>
<tr>
<td>Group II</td>
<td>6.45±1.5</td>
<td>6.3±1.42</td>
<td>6.3±1.42</td>
<td>4.25±1.7</td>
<td></td>
</tr>
</tbody>
</table>

### TABLE IV: QUALITY OF LIFE SCORE FOR FREQUENCY STATEMENT

<table>
<thead>
<tr>
<th></th>
<th>1&lt;sup&gt;st&lt;/sup&gt; day</th>
<th>45&lt;sup&gt;th&lt;/sup&gt; day</th>
<th>52&lt;sup&gt;nd&lt;/sup&gt; day</th>
<th>97&lt;sup&gt;th&lt;/sup&gt; day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>66.5±15.4</td>
<td>38.8±21.5</td>
<td>38.8±21.5</td>
<td>36.65±21.5</td>
</tr>
<tr>
<td>Group II</td>
<td>59.57±16.4</td>
<td>59.4±16.3</td>
<td>59.4±16.3</td>
<td>48.5±7.5</td>
</tr>
</tbody>
</table>

### TABLE V: QUALITY OF LIFE SCORE FOR SEVERITY STATEMENT

<table>
<thead>
<tr>
<th></th>
<th>1&lt;sup&gt;st&lt;/sup&gt; day</th>
<th>45&lt;sup&gt;th&lt;/sup&gt; day</th>
<th>52&lt;sup&gt;nd&lt;/sup&gt; day</th>
<th>97&lt;sup&gt;th&lt;/sup&gt; day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>68.73±18.7</td>
<td>42.33±24.8</td>
<td>42.33±24.8</td>
<td>42.21±24.9</td>
</tr>
<tr>
<td>Group II</td>
<td>67.37±19.7</td>
<td>67.19±19.5</td>
<td>67.19±19.5</td>
<td>48.8±22.37</td>
</tr>
</tbody>
</table>

### TABLE VI: TINNITUS MATCHING FOR LOUDNESS IN DB

<table>
<thead>
<tr>
<th></th>
<th>1&lt;sup&gt;st&lt;/sup&gt; day</th>
<th>45&lt;sup&gt;th&lt;/sup&gt; day</th>
<th>52&lt;sup&gt;nd&lt;/sup&gt; day</th>
<th>97&lt;sup&gt;th&lt;/sup&gt; day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>50.5±20.5</td>
<td>43±23.9</td>
<td>43±23.9</td>
<td>43±23.9</td>
</tr>
<tr>
<td>Group II</td>
<td>49±20.17</td>
<td>49±20.17</td>
<td>49±20.17</td>
<td>40.5±24.05</td>
</tr>
</tbody>
</table>

### TABLE VII AND GRAPH I: %AGE OF PATIENTS SHOWING IMPROVEMENT IN TINNITUS LOUDNESS

<table>
<thead>
<tr>
<th>Drugs modulating GABA neurotransmission</th>
<th>Alprazolam</th>
<th>Clonazepam</th>
<th>Gabapentine</th>
</tr>
</thead>
<tbody>
<tr>
<td>%age of patients showing improvement in tinnitus loudness</td>
<td>65%</td>
<td>32%</td>
<td>59%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drugs modulating GABA neurotransmission</th>
<th>Caroverine</th>
<th>Memantine</th>
<th>Acamprosate</th>
</tr>
</thead>
<tbody>
<tr>
<td>%age of patients showing improvement in tinnitus loudness</td>
<td>63%</td>
<td>37.2%</td>
<td>87%</td>
</tr>
</tbody>
</table>